Lilly Alzheimer’s drug fails to slow mem­ory loss in big study

Kuwait Times - - HEALTH & SCIENCE -

Eli Lilly and Co ex­per­i­men­tal drug solanezumab failed to slow loss of cog­ni­tive abil­ity in pa­tients with mild Alzheimer’s dis­ease in a large trial, a ma­jor set­back for the US drug­maker and mil­lions of peo­ple with the mem­ory-rob­bing dis­ease. Based on the fail­ure of the Phase III study, Lilly yes­ter­day said it would not seek US ap­proval of the in­fused drug for mild de­men­tia. Some an­a­lysts had pre­dicted solanezumab, if ap­proved, could even­tu­ally claim more than $5 bil­lion in an­nual sales and boost Lilly’s earn­ings for years to come. — Reuters

KUANTAN, Malaysia: A wild macaque mon­key holds a toy sword left by a pedes­trian at Teluk Cempedak beach on the out­skirts of Kuantan, penin­su­lar Malaysia’s north­east­ern Pa­hang state. Fe­male vervet mon­keys ma­nip­u­late males into fight­ing bat­tles by lav­ish­ing at­ten­tion on brave sol­diers while giv­ing non­com­bat­ants the cold shoul­der, re­searchers said on yes­ter­day. — AFP

Newspapers in English

Newspapers from Kuwait

© PressReader. All rights reserved.